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Neutropenia Based on Pharmacokinetic and Pharmacody-
namic Findings
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Objectives: Cefepime (CFPM) is being used worldwide for
febrile neutropenia (FN) with three administrations per day
(q8h), but because no population pharmacokinetics analysis
has been performed yet, the optimal CFPM administration
method remains unknown.
Methods: We conducted a prospective clinical trial of
CFPM among adult hematological patients with FN. CFPM
was administered with a daily dose of 4 g (1 g at 10:00,
1 g at 16:00, 2 g at 22:00 hours). NONMEM software was
used for the population pharmacokinetic analysis. Monte
Carlo simulation was performed based on the data of min-
imum inhibitory concentration (MIC) frequency distribution
of main bacteria strains gathered at our institute.
Results: Intravenous CFPM was administered for 101
episodes of FN. A high percentage of these episodes was
treated successfully (69.2%). The NONMEM program demon-
strated that a 2-compartment model with CL of 4.23(L/hr),
V1 of 12.0(L), Q of 3.98 (L/hr), and V2 of 3.40(L) ﬁts the
data best. Monte Carlo simulation indicated that the pro-
portion of simulated patients with probability of attainment
above target (time above MIC = 70%) was greater among
those treated with the thrice-a-day method than with the
twice-a-day method. Time above MIC for administration at
irregular time intervals was similar to that for q8h adminis-
tration.
Conclusions: Our administration method appears to be
the most suitable for FN patients. With this method, late
night and early morning drip infusion as well as the incon-
venience of maintaining exact 8 h intervals can be avoided.
doi:10.1016/j.ijid.2008.05.269
17.004
Qnr Prevalence of Plasmid-Mediated Quionlone Resis-
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Objective: To explore distribution of qnrA,qnrB,qnrS
genes in gram-negative bacteria isolates in Renmin Hospital
of Wuhan University.
Methods: qnr genes in nonrepetitive 129 iaolates of E.coli
and 13 isolates of E.cloacac and 37 isolates of K. pneunoniae
were detected by PCR. Susceptibility test to 15 antibiotics
were also performed by K-B in virto. MICs of ciproﬂoxacin
were determined by agar dilution technique. Plasmid con-
jugatable test was applied to examine whether qnr gene
located in conjugatable plasmid or not. IntI were detected
by PCR.
Results: Among 179 gram negative bacteria isolates, the
qnrA genes were present in 3.88% of E.coli and 7.69% of
E.cloaca. The qnrB genes were present in 6.20% of E.coli
and 7.69% of E.cloaca. The qnrS genes were present in 2.33%
of E.coli and 18.92% of K. pneumoniae. All positive isolates
were suspectible to imipenem but resistance to some other
drugs. 2 qnrA positive isolates and 4 qnrB positive isolates of
were susceptible to ciproﬂoxacin. Qnr gene were on trans-
ferable plasmids and could be dsseminated by clone. 23 of
them were I type integron-positive isolates.
Conclusions: In HuBei province, the prevalence of qnr is
comﬁrmed and we ﬁnd qnr genes could also be in quinolone
suspectible strains. So it is necessary to study the prevalence
and mechanism of qnr genes of quinolones resistance further
in the future.
doi:10.1016/j.ijid.2008.05.270
17.005
Fluoroquinolone Resistance in Clinical Isolates of Kleb-
siella oxytoca
T. Horii 1,∗, M. Osaki2
1 Department of Microbiology and Immunology, Tottori Uni-
versity Faculty of Medicine and Tottori University Hospital,
Yonago, Japan
2 Department of Microbiology and Immunology, Tottori Uni-
versity Faculty of Medicine, Yonago, Japan
Background: Prevalence of ﬂuoroquinolone-resistant
Klebsiella oxytoca has been reported worldwide.
Methods: We recovered twelve clinical K. oxytoca iso-
lates from patients with acute urinary tract infections,
asymptomatic bacteriuria or acute bacillary diarrhea in
Japan. Fluoroquinolone resistance was characterized genet-
ically by PCR and DNA sequencingmethods. Outer membrane
protein (OMP) proﬁles were determined by SDS-PAGE.
Results: In 11 clinical isolates of levoﬂoxacin-resistant K.
oxytoca, nucleotide sequences in the quinolone resistance-
determining regions showed amino acid mutations such as
Thr83Ile and Asp87Gly in GyrA and Ser80Ile in ParC. Com-
bined effects of reduced 36-kDa OMP production and amino
acid mutations in GyrA and ParC were shown by four K. oxy-
toca isolates exhibiting higher MICs for ﬂuoroquinolones than
other ﬂuoroquinolone-resistant isolates.
Conclusion: We identiﬁed multiple mechanisms of ﬂuo-
roquinolone resistance in K. oxytoca clinically isolated in
Japan, including reduction of 36-kDa OMP production as well
as GyrA and ParC mutations.
doi:10.1016/j.ijid.2008.05.271
